Information  X 
Enter a valid email address

Avacta Group PLC (AVCT)

  Print   

Tuesday 02 February, 2021

Avacta Group PLC

Issue of Equity

RNS Number : 6886N
Avacta Group PLC
02 February 2021
 

 

 

 

 

 

02 February 2021

 

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

Issue of Equity

 

Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, today announces that, following the exercise of share options by Bach Biosciences LLC ("Bach"), it has issued and allotted in total 580,791 new ordinary shares of 10 pence each in the Company ("Ordinary Shares"). The exercise by Bach follows the successful submission of the Clinical Trial Application to the UK Medicines and Healthcare Products Regulatory Agency for AVA6000 Pro-doxorubicin on 23 December 2020. The exercise also reflects Avacta's ongoing, close collaboration with Professor William Bachovchin to develop a pipeline of pre|CISION chemotherapies based on the FAP sensitive substrate developed by Professor Bachovchin at Tufts University School of Medicine and exclusively licensed by Avacta.

 

Application will be made for the Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 8 February 2021 . The Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company.

 

Following Admission, the Company's enlarged issued share capital will be 253,236,345. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

-Ends -

 

 

For further information from Avacta Group plc, please contact:

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

 

Tel: +44 (0) 844 414 0452

www.avacta.com

 

 

 

finnCap Ltd (Nomad and Joint Broker)

Geoff Nash / Giles Rolls / Teddy Whiley - Corporate Finance

Tim Redfern - ECM

Tel: +44 (0) 207 220 0500

www.finncap.com

 

 

 

 

Stifel Nicolaus Europe Limited  (Joint Broker)

 

Tel: +44 (0) 207 710 7600

 

Nicholas Moore / Nick Adams / Fred Walsh / Ben Maddison

www.stifel.com

 

 

FTI Consulting (Financial Media and IR)

Tel: +44 (0) 203 727 1000

 

Simon Conway / Stephanie Cuthbert

[email protected] ticonsulting .com



 

 

 

Zyme Communications  (Trade and Regional Media)

Katie Odgaard

 

 

 

Tel: +44 (0)7787 502 947

[email protected]  

 

 

 

About Avacta Group plc -   https://www.avacta.com

 

Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.

The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance on an animal's immune response; poor specificity in many cases; their large size, complexity and high cost of manufacture. 

Avacta's pre|CISION targeted chemotherapy platform releases active chemotherapy in the tumour, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these powerful anti-cancer treatments. 

The Group comprises two divisions: The therapeutics development activities are based in Cambridge, UK and the Group is generating near-term revenues from Affimer reagents for diagnostics, bioprocessing and research, through a separate diagnostics business unit based in Wetherby, UK.

Avacta's Diagnostics Division works with partners world-wide to develop bespoke Affimer reagents for third party products. The Company is also developing an in-house pipeline of Affimer-based diagnostic assays including the AffiDXTM SARS-CoV-2 Lateral Flow Rapid Antigen Test and a BAMSTM SARS-CoV-2 Assay in partnership with Adeptrix Inc.

Avacta's Therapeutics Division is addressing a critical gap in current cancer treatment - the lack of a durable response to current immunotherapies experienced by most patients. By combining its two proprietary platforms the Company is building a wholly owned pipeline of novel cancer therapies deigned to be effective for all cancer patients. In 2021 Avacta will commence a phase 1 first-in-human, open label, dose-escalation and expansion study of AVA6000 Pro-doxorubicin, the Company's lead pre|CISIONTM prodrug, in patients with locally advanced or metastatic selected solid tumours.

Avacta has established drug development partnerships with pharma and biotech, including a research collaboration with Moderna Therapeutics Inc., a deal with LG Chem worth up to $400m, a partnership with ADC Therapeutics and a collaboration with Point Biopharma to develop radiopharmaceuticals based on the pre|CISIONTM platform. Avacta actively seeks to license its proprietary platforms in a range of therapeutic areas.

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

 

 

 

About Bach Biosciences LLP

Bach Biosciences LLP is the mission-driven development company associated with Dr. William Bachovchin's laboratory at Tufts University School of Medicine. Bach Biosciences is accelerating breakthrough discoveries into therapeutics for patients, from its own drug development pipeline or by working in partnership with other life science companies.  Bach Biosciences' leadership and development team is highly skilled in translational medicine and pharmaceutical development, having had a number of programs move into clinical development and into the marketplace.  The company and its founders have established strategic partnerships with contract research organizations, investors, and pharmaceutical partners to support technology development.  Dr. Bachovchin is the inventor on 46 issued US patents, including reach-through patents covering the field of DPP-IV inhibitors for treating diabetes, a $10B market. This patent has been licensed by Merck, Novartis, Bristol-Myers Squibb and Boehringer Ingelheim. In addition three drugs first designed, synthesized and characterized in Dr. Bachovchin's laboratory at Tufts University School of Medicine have been advanced into human clinical trials.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEUURWRABUURRR

a d v e r t i s e m e n t